IRIDEX Corporation — FY 2018 Form 10-K
Reporting period: Fiscal year ended December 29, 2018 (52 weeks), compared with the 52-week fiscal year ended December 30, 2017. Although the request references 2018 Q4, this filing is an annual report and does not provide a clear standalone fourth-quarter financial summary.
Business context
IRIDEX develops, manufactures and sells ophthalmic laser systems, delivery devices and consumables used to treat glaucoma and retinal diseases. Its proprietary MicroPulse technology is used in certain products. Revenue includes console and delivery-system sales, recurring consumables, service and support, and royalties. U.S. and German sales are primarily direct; other international sales are mainly through distributors.
Financial results and liquidity
| Metric | FY 2018 | FY 2017 |
|---|---|---|
| Revenue | $42.6 million | $41.6 million |
| Gross profit / gross margin | $17.5 million / 41.0% | $15.5 million / 37.3% |
| Operating loss | $12.9 million | $12.9 million |
| Net loss | $12.8 million | $12.9 million |
| Basic and diluted loss per share | $1.05 | $1.11 |
| Net cash used in operating activities | $10.0 million | $3.6 million |
- Cash and cash equivalents were $21.2 million at year-end, versus $21.7 million a year earlier; working capital was $28.5 million versus $29.1 million.
- The company reported no borrowings at year-end. Its $15 million accounts-receivable-based revolving facility with Silicon Valley Bank was undrawn and scheduled to mature November 2, 2019.
- Financing activities provided $10.4 million, including approximately $10.5 million net proceeds from a September 2018 public stock offering. Shares outstanding increased to 13.6 million from 11.6 million.
- Management said existing cash and cash equivalents should meet anticipated cash needs for the next 12 months. No quantified revenue, earnings or margin guidance was provided.
Material changes versus FY 2017
- Revenue grew 2.4%. International systems revenue increased to $12.7 million from $11.7 million, and recurring revenue increased to $22.6 million from $21.9 million. Domestic systems revenue declined to $7.3 million from $8.0 million.
- Gross margin improved 3.7 percentage points, attributed mainly to lower manufacturing costs and the absence of costs associated with the 2017 LIO recall, partly offset by geographic mix.
- Sales and marketing expense rose to $16.8 million from $14.5 million, while R&D expense fell to $4.0 million from $5.2 million. General and administrative expense increased to $9.6 million from $8.8 million.
- Operating cash use increased substantially, principally due to working-capital movements, lower cash collections, vendor-payment timing and higher operating expenses.
- The company recorded a full valuation allowance on federal and state deferred tax assets in Q4, citing its history and forecast of losses. The year-end valuation allowance was $15.5 million.
Outlook, risks and unusual items
- Product recall: A worldwide voluntary recall of the TruFocus LIO Premiere began February 23, 2018, following reports of three adverse events involving focal cataracts and iris burns. The filing expected the recall to be completed by the end of FY 2019 Q1. An updated device received FDA clearance; further adverse events, market acceptance and launch costs remain concerns.
- Regulatory: IRIDEX needed to obtain ISO 13485:2016 certification through the Medical Device Single Audit Program by December 31, 2019 to continue sales in Canada. European medical-device regulatory changes may increase compliance costs and lengthen product launch cycles.
- Operations and competition: The company cites prior supply-chain, production and training issues; dependence on sole- or limited-source suppliers; intense competition; and reliance on international distributors and markets. International revenue was $20.5 million, or 48.1% of total revenue.
- Reimbursement and clinical adoption: Changes in payer coverage or reimbursement, uncertain clinical evidence and limited adoption of new products or procedures could constrain demand.
- Commitments: Contract manufacturing and supply commitments totaled $10.4 million, including $9.0 million due in 2019. Future minimum operating lease payments totaled $4.7 million. Adoption of the new lease standard was expected to add approximately $4.0 million of right-of-use assets and $4.5 million of lease liabilities at the start of FY 2019.
- Legal/IP: IRIDEX and Quantel resolved their dispute in February 2019; IRIDEX dismissed its U.S. lawsuit and Quantel ceased participation in parallel European proceedings. The European Patent Office had issued a decision to revoke a disputed European patent, which IRIDEX appealed in October 2018; the filing does not clearly state the appeal’s disposition.
- The independent auditor issued an unqualified opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor was not required to attest to internal control effectiveness.
Important facts for investors to verify
- Whether operating cash use and collections improve, and how long available cash can support operations without further financing.
- Whether the updated LIO completes the recall process safely and gains market acceptance, including any subsequent adverse-event or recall disclosures.
- Progress on Canadian MDSAP certification and compliance with evolving EU medical-device requirements.
- Trends in domestic system sales, G6-related probe growth, recurring revenue and gross margin, including the durability of FY 2018 margin improvement.
- Status and terms of the Quantel settlement and any remaining European patent appeal or other intellectual-property proceedings.
- Availability and borrowing-base capacity of the revolving credit facility, and the impact of lease-standard adoption and committed supplier payments on liquidity.